Genomics market to reach $157.5 billion by 2033

The global genomics market is set to grow more than fourfold from $39.5 billion in 2024 to $157.5 billion by 2033, at a compound annual growth rate (CAGR) of 16.6%. Similarly, the human microbiome market is anticipated to grow from $814 million in 2024 to over $4.2 billion by 2030, reflecting a CAGR of 31.5%. These figures underscore the transformative potential of genomic and microbiome sciences in revolutionizing personalized medicine.

On December 11, 2024, at the Palace Downtown, Dubai, CE-Ventures, the corporate venture capital arm of Crescent Enterprises, will host a symposium titled “The Microbiome and Genomics Revolution: Personalising Medicine for Health and Longevity.”

This event seeks to advance personalized and preventive healthcare by gathering leading experts to discuss the application of microbiome science and genomics in personalized medicine. This exploration focuses on how current research and innovative techniques can be applied to develop more tailored medical treatments. The symposium will serve as a collaborative platform to discuss the intersection of microbiome science, genomics, and artificial intelligence in tackling global health challenges. The program will feature keynote addresses and panel discussions that delve into critical themes such as chronic disease management, longevity, immune health, and the ethical considerations of equitable access to emerging healthcare technologies.

Tushar Singhvi, Deputy CEO and Head of Investments at Crescent Enterprises, highlighted the importance of this growth: “As we stand at the forefront of a healthcare revolution, the convergence of microbiome science and genomics offers transformative possibilities to personalize treatments and improve health outcomes. This symposium reflects Crescent Enterprises’ dedication to fostering collaboration and translating scientific advancements into practical solutions that benefit communities worldwide”.

CE-Ventures has long demonstrated its commitment to advancing healthcare innovation through strategic investments. Companies such as Freya Biosciences, which focuses on microbial immunotherapies for reproductive health, and Exeliom Biosciences, a leader in leveraging microbiome science for chronic disease interventions, exemplify this dedication. These investments underscore CE-Ventures’ vision of bridging the gap between groundbreaking research and real-world healthcare applications.